Tags

Type your tag names separated by a space and hit enter

Limitations to the use of bromelain-based enzymatic debridement (NexoBrid®) for treating diabetic foot burns: a case series of disappointing results.
Scars Burn Heal 2018 Jan-Dec; 4:2059513118816534SB

Abstract

Background

Bromelain-based enzymatic debridement with Nexobrid® (Mediwound) is an alternative to traditional surgical tangential excision of deep dermal and full thickness burns. Early literature suggests that Nexobrid debridement could reduce the number of operations, infection rates, inpatient stay and the necessity for skin grafting to wounds by preserving viable tissue. To our knowledge there are no previous studies reporting the use of NexoBrid for treating burns in patients with established diabetic foot disease.

Case presentation

We conducted a retrospective case series and identified four patients with diabetic foot burns that were treated with Nexobrid® debridement. All of these patients developed further eschar and deepening of their wounds a few days after NexoBrid was applied, requiring further surgery and skin grafting.

Conclusions

We would recommend judicious use of this new product in patients with diabetic foot wounds.

Authors+Show Affiliations

Queen Victoria Hospital NHS Foundation Trust, East Grinstead, UK. Kellogg College, University of Oxford, Oxford, UK.Queen Victoria Hospital NHS Foundation Trust, East Grinstead, UK.Queen Victoria Hospital NHS Foundation Trust, East Grinstead, UK.Queen Victoria Hospital NHS Foundation Trust, East Grinstead, UK.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

30574406

Citation

Berner, Juan Enrique, et al. "Limitations to the Use of Bromelain-based Enzymatic Debridement (NexoBrid®) for Treating Diabetic Foot Burns: a Case Series of Disappointing Results." Scars, Burns & Healing, vol. 4, 2018, p. 2059513118816534.
Berner JE, Keckes D, Pywell M, et al. Limitations to the use of bromelain-based enzymatic debridement (NexoBrid®) for treating diabetic foot burns: a case series of disappointing results. Scars Burn Heal. 2018;4:2059513118816534.
Berner, J. E., Keckes, D., Pywell, M., & Dheansa, B. (2018). Limitations to the use of bromelain-based enzymatic debridement (NexoBrid®) for treating diabetic foot burns: a case series of disappointing results. Scars, Burns & Healing, 4, p. 2059513118816534. doi:10.1177/2059513118816534.
Berner JE, et al. Limitations to the Use of Bromelain-based Enzymatic Debridement (NexoBrid®) for Treating Diabetic Foot Burns: a Case Series of Disappointing Results. Scars Burn Heal. 2018;4:2059513118816534. PubMed PMID: 30574406.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Limitations to the use of bromelain-based enzymatic debridement (NexoBrid®) for treating diabetic foot burns: a case series of disappointing results. AU - Berner,Juan Enrique, AU - Keckes,Dejan, AU - Pywell,Matthew, AU - Dheansa,Baljit, Y1 - 2018/12/05/ PY - 2018/12/22/entrez PY - 2018/12/24/pubmed PY - 2018/12/24/medline KW - Enzymatic debridement KW - NexoBrid KW - bromelain KW - burns KW - contact KW - diabetic KW - foot SP - 2059513118816534 EP - 2059513118816534 JF - Scars, burns & healing JO - Scars Burn Heal VL - 4 N2 - Background: Bromelain-based enzymatic debridement with Nexobrid® (Mediwound) is an alternative to traditional surgical tangential excision of deep dermal and full thickness burns. Early literature suggests that Nexobrid debridement could reduce the number of operations, infection rates, inpatient stay and the necessity for skin grafting to wounds by preserving viable tissue. To our knowledge there are no previous studies reporting the use of NexoBrid for treating burns in patients with established diabetic foot disease. Case presentation: We conducted a retrospective case series and identified four patients with diabetic foot burns that were treated with Nexobrid® debridement. All of these patients developed further eschar and deepening of their wounds a few days after NexoBrid was applied, requiring further surgery and skin grafting. Conclusions: We would recommend judicious use of this new product in patients with diabetic foot wounds. SN - 2059-5131 UR - https://www.unboundmedicine.com/medline/citation/30574406/Limitations_to_the_use_of_bromelain_based_enzymatic_debridement__NexoBrid®__for_treating_diabetic_foot_burns:_a_case_series_of_disappointing_results_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30574406/ DB - PRIME DP - Unbound Medicine ER -